Danaher Stock Earnings Reports

Danaher reported a solid start to 2026 with first quarter sales of $6.0B, core revenue up 0.5% (impacted by a ~2.5% respiratory headwind) and adjusted diluted EPS of $2.06, up 9.5% year-over-year. Gross margin was 60.3% and adjusted operating margin 30.2%, aided by cost savings and productivity. The company generated $1.1B of free cash flow in Q1 (105% FCF/net income conversion) and reiterated core revenue guidance of 3%–6% for 2026 while raising full-year adjusted diluted EPS guidance modestly to $8.35–$8.55. Key business highlights: strong bioprocessing performance (bioprocessing core + high single digits; equipment orders >30% YoY), improving Life Sciences trends (notably Abcam and Aldevron) and stable non-respiratory Diagnostics growth offsetting a lighter respiratory season at Cepheid (respiratory down ~25% YoY in Q1). China showed acceleration in Life Sciences and Biotechnology; Diagnostics in China continues to face volume-based procurement/reimbursement pressure. Management emphasized disciplined capital deployment and announced the pending acquisition of Masimo, which they expect to be accretive in year one post-close and to deliver high single-digit ROIC by year five. They see AI as a multi-year growth tailwind across discovery, development and manufacturing. Near-term headwinds (China diagnostics policy, respiratory seasonality and some Life Sciences comps) amount to ~300 basis points in the first half but are expected to abate such that Danaher can exit Q4 at mid-single-digit core revenue growth. The balance sheet and robust free cash flow position Danaher to pursue further M&A while continuing organic investments.